Pfizer Sponsor - Search News

Pfizer Clinches Deal for Obesity Drug Developer Metsea

Digest more

· 7d · on MSN

Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up

Pfizer has filed two lawsuits against Metsera, its board, and Novo Nordisk.

· 2d · on MSN

Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk

MedCity News · 7d

Pfizer Lawsuits Allege Novo Nordisk’s Bid to Buy Obesity Biotech Metsera is Anticompetitive, Illegal

· 1d

Pfizer shows hardball mettle needed to win in 2025 M&A

On September 22, Pfizer announced a deal to acquire the shares of promising weight-loss drug start-up Metsera for $5.5bn.

· 23h

Metsera shares fall as Pfizer-Novo Nordisk bidding war comes to an end

· 1d

Novo Nordisk stock rises as drugmaker drops out of bidding war for Metsera

Fortune India

Pfizer acquires start-up Metsera for $10 billion; know the leaders behind the small biopharma company

Pharmaceutical giant Pfizer has finally acquired development-stage obesity drugmaker Metsera Inc., in an intense bidding war against the Danish drugmaker Novo Nordisk for over $10 billion.

TipRanks on MSN

Pfizer’s Ongoing Palbociclib Study: A Commitment to Cancer Treatment Safety

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Study Overview: Pfizer Inc. is conducting a clinical study titled ‘A

7don MSN

Novo Nordisk CEO Faces Baptism of Fire Amid Board Shakeup, Pfizer Fight

LONDON (Reuters) -Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues a bidding war with U.S. rival Pfizer. The drugmaker will release third quarter results on Wednesday, the first for Mike Doustdar who was tasked in August with turning around the Danish company's fortunes.